Explore

Rapid ReadRapid Read
mRNA Vaccine Technology Expands Beyond COVID-19 to Include RSV, Influenza, and Cancer Treatments

mRNA Vaccine Technology Expands Beyond COVID-19 to Include RSV, Influenza, and Cancer Treatments

mRNA vaccine technology, initially prominent for COVID-19, is now being applied to a broader range of infectious diseases and cancer treatments. These vaccines utilize messenger RNA (mRNA) to instruct cells to produce specific antigens, thereby stimulating an immune response. The mRNA is delivered into cells encapsulated in lipid nanoparticles, which protect the RNA strands and aid absorption. Currently, mRNA vaccines are in clinical and commercial use for COVID-19, with annual updates targeting circulating SARS-CoV-2 variants. Moderna's mRESVIA is approved for Respiratory Syncytial Virus (RSV) in adults aged 60 and older, with expanded authorization for high-risk individuals aged 18 to 59. Additionally, Moderna's mRNA-1010 (mFLUSIVA) influenza vaccine has received FDA approval, and combined flu-and-COVID booster shots are in late-stage clinical trials. Beyond infectious diseases, personalized mRNA cancer therapies, such as Moderna and Merck’s mRNA-4157, are in late-stage clinical trials for melanoma and a...
Rapid ReadRapid Read
FDA Approves New Cancer Therapies for Bladder and Rectal Cancers, Expands Keytruda Indication

FDA Approves New Cancer Therapies for Bladder and Rectal Cancers, Expands Keytruda Indication

The U.S. Food and Drug Administration (FDA) has recently approved several new cancer treatments and expanded indications for existing therapies. On October 14, 2026, the FDA approved nogapendekin alfa inbakicept-pmln (Anktiva) in combination with bacillus Calmette-Guérin (BCG) for adults with BCG-unresponsive non–muscle-invasive bladder cancer (NMIBC). This approval expands the prior indication to include patients with high-grade papillary-only tumors, based on the efficacy demonstrated in the QUILT-3.032 trial. Additionally, on October 16, 2026, the FDA granted traditional approval to pembrolizumab (Keytruda) or pembrolizumab and berahyaluronidase alfa-pmph (Keytruda Qlex) for adult and pediatric patients with unresectable or metastatic tumor mutational burden–high (TMB-H) solid tumors. This converts a previous accelerated approval and refines the TMB-H definition to ≥ 13 mutations/megabase. Furthermore, on October 19, 2026, the PD-1 inhibitor dostarlimab (Jemperli) received accelerated approval for adult...
Rapid ReadRapid Read
IASO Bio's In Vivo CAR-T Therapy Receives Simultaneous FDA and NMPA IND Approvals

IASO Bio's In Vivo CAR-T Therapy Receives Simultaneous FDA and NMPA IND Approvals

IASO Bio's IASO208, an in vivo CAR-T therapy targeting CD20, has achieved simultaneous Investigational New Drug (IND) clearances from both the U.S. Food and Drug Administration (FDA) and China's National Medical Products Administration (NMPA). The FDA implicitly cleared the IND in September 2026, followed by the NMPA's approval this month through China's 30-day expedited review pathway. This dual clearance allows IASO Bio to leverage its existing clinical data from China to initiate Phase Ib studies in the United States, with plans for larger trials across both regions. The in vivo CAR-T approach, where the gene-editing vector reprograms T cells inside the patient's body, represents a significant advancement compared to current ex vivo CAR-T therapies that require external cell engineering. Early data from an ongoing investigator-initiated trial (IIT) in China involving eleven patients showed favorable tolerability and promising anti-tumor activity, which was presented at the 2026 ASH Annual Meeting.
Rapid ReadRapid Read
Experimental Drug Eliminates Aggressive Pancreatic Tumors in Mice, Enhances Immune Memory

Experimental Drug Eliminates Aggressive Pancreatic Tumors in Mice, Enhances Immune Memory

Preclinical findings from an international research study, co-authored by Dr. John J. Letterio of University Hospitals Rainbow Babies & Children's Hospital, reveal an experimental drug's significant impact on aggressive pancreatic tumors. The drug, FEBP-sTβRII, eliminated 75% of aggressive pancreatic tumors in mouse models and enhanced immune system memory to combat other cancers. Many solid tumors, including pancreatic, breast, colon, and lung cancers, create a dense, scar-like tissue barrier that prevents immune system T cells from attacking. This barrier is largely due to a signaling molecule called TGF-β, which promotes fibrous tissue growth and suppresses immune cells. Previous attempts to block TGF-β systemically have been unsuccessful due to toxicity at effective doses. This new drug is engineered with a tag that specifically targets a form of fibronectin abundant in tumors but rare in healthy tissue, allowing it to concentrate in the tumor and break down this protective barrier from within. Once th...
Rapid ReadRapid Read
Lustgarten Foundation Scientific Advisory Board Outlines Strategic Direction for Pancreatic Cancer Treatments

Lustgarten Foundation Scientific Advisory Board Outlines Strategic Direction for Pancreatic Cancer Treatments

The Lustgarten Foundation, the largest private funder of pancreatic cancer research, recently convened its Scientific Advisory Board (SAB) to establish the strategic direction for the next generation of pancreatic cancer treatments. Following a year of significant scientific progress, including the FDA approval of the RAS-targeted therapy RASONQUE™ (daraxonrasib), the meeting focused on building upon these breakthroughs to develop more effective and durable treatments. Key areas of discussion included advancing methods to measure treatment response, understanding treatment failure and resistance, identifying new therapeutic targets and combinations, advancing prevention and interception strategies, and innovating clinical trial design. A central theme was the importance of integrating clinical observations, biological insights, and new methods for measuring treatment response to guide more personalized treatment strategies. The Foundation awarded $22.8 million in new research funding in fiscal year 2026, a...
Rapid ReadRapid Read
European Innovation Council Funds Research for mRNA Liver Cancer Vaccine Development

European Innovation Council Funds Research for mRNA Liver Cancer Vaccine Development

The European Innovation Council (EIC) has allocated approximately €3.8 million in funding to the international research project ADVANCE. This project, involving Universitatsmedizin Frankfurt, aims to develop an mRNA-based cancer vaccine for hepatocellular carcinoma (HCC), the most common form of liver cancer. The vaccine is designed to train the immune system to recognize novel target structures, specifically 'dark peptides' that become more prevalent in tumor cells under cellular stress, but are largely absent from healthy tissue. Researchers, including Dr. Andreas Schlosser from Universitatsmedizin Frankfurt, are using mass spectrometry, RNA sequencing, and artificial intelligence to identify these tumor-specific peptides. The mRNA containing instructions for producing these peptides will be encapsulated in lipid nanoparticles for delivery, aiming to trigger a targeted T-cell response to attack liver cancer cells. This initiative seeks to overcome the challenge of cancer cells evading immune surveillance...
Rapid ReadRapid Read
Dr. C. Ola Landgren to Receive PMWC Pioneer Award for Advancing Minimal Residual Disease in Multiple Myeloma

Dr. C. Ola Landgren to Receive PMWC Pioneer Award for Advancing Minimal Residual Disease in Multiple Myeloma

C. Ola Landgren, M.D., Ph.D., director of Sylvester Myeloma Institute at Sylvester Comprehensive Cancer Center, will receive the Precision Medicine World Conference (PMWC) Pioneer Award in January 2027. This recognition is for his significant contributions to advancing minimal residual disease (MRD) as an earlier and more precise measure of treatment effectiveness in multiple myeloma. MRD refers to the tiny number of cancer cells that remain during remission, detectable only by highly sensitive laboratory methods. Dr. Landgren's work has been instrumental in helping new therapies demonstrate effectiveness more quickly, potentially accelerating their availability to patients. His team is also leading research into bispecific T-cell therapies, including strategies to safely deliver these treatments and manage side effects like cytokine release syndrome. This research extends to other cancers, such as lymphoma and rare gynecologic neuroendocrine cancers, demonstrating a continuous cycle of measurement, learni...
TrendlineTrendline
Natera and Incyte Collaborate on Phase II Colorectal Cancer Study Utilizing Signatera MRD Testing

Natera and Incyte Collaborate on Phase II Colorectal Cancer Study Utilizing Signatera MRD Testing

Natera and Incyte Collaborate on Phase II Colorectal Cancer Study Utilizing Signatera MRD Testing
Rapid ReadRapid Read
mRNA COVID-19 Vaccines Show Unexpected Benefits in Cancer Treatment and Prevention

mRNA COVID-19 Vaccines Show Unexpected Benefits in Cancer Treatment and Prevention

Recent scientific findings indicate that mRNA COVID-19 vaccines may offer unexpected benefits beyond their primary role in preventing viral infection. Researchers have discovered that receiving an mRNA COVID shot can enhance the effectiveness of certain cancer therapies, leading to improved three-year survival rates for patients. This breakthrough has spurred pharmaceutical companies to explore and develop personalized cancer vaccines utilizing mRNA technology. These new vaccines aim to target individual patients' tumors, representing a significant advancement in oncology. This development highlights how scientific innovations, even when focused on one area, can yield unforeseen positive outcomes in other critical public health domains. The initial success in improving cancer therapy efficacy suggests a broader potential for mRNA technology in medical treatments.
TrendlineTrendline
ImmunityBio Reports Expanded FDA Approval for ANKTIVA and Strong Q3 2026 Revenue Growth

ImmunityBio Reports Expanded FDA Approval for ANKTIVA and Strong Q3 2026 Revenue Growth

ImmunityBio Reports Expanded FDA Approval for ANKTIVA and Strong Q3 2026 Revenue Growth
TrendlineTrendline
Precision for Medicine Seeks Resource Manager to Optimize Oncology Development Pathway

Precision for Medicine Seeks Resource Manager to Optimize Oncology Development Pathway

Precision for Medicine Seeks Resource Manager to Optimize Oncology Development Pathway
TrendlineTrendline
Immunome Reports Strong Q3 2026 Financial Results and Advances Oncology Pipeline with New Clinical Trials

Immunome Reports Strong Q3 2026 Financial Results and Advances Oncology Pipeline with New Clinical Trials

Immunome Reports Strong Q3 2026 Financial Results and Advances Oncology Pipeline with New Clinical Trials